Financials Modus Therapeutics Holding AB
Equities
MODTX
SE0015987904
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 SEK | -3.70% |
|
+0.48% | -40.06% |
Valuation
Fiscal Period: December | 2021 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 61.18 | 62.35 | 37.38 | - | - |
Enterprise Value (EV) 1 | 61.18 | 62.35 | 36.38 | -7.624 | 30.38 |
P/E ratio | - | -1.72 x | -2.08 x | -1.04 x | -0.98 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | -2.96 x | - | -2.02 x | 0.21 x | -0.8 x |
EV / FCF | - | - | -2.02 x | 0.21 x | -0.8 x |
FCF Yield | - | - | -49.5% | 472% | -125% |
Price to Book | - | - | -104 x | 0.85 x | 6.5 x |
Nbr of stocks (in thousands) | 16,100 | 35,939 | 35,939 | - | - |
Reference price 2 | 3.800 | 1.735 | 1.040 | 1.040 | 1.040 |
Announcement Date | 22/02/22 | 21/02/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales | 0.002 | - | - | - | - | - |
EBITDA 1 | - | -20.69 | - | -18 | -36 | -38 |
EBIT 1 | - | -20.69 | - | -18 | -36 | -38 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | - | -18 | -36 | -38 |
Net income 1 | -6.019 | - | -17.9 | -18 | -36 | -38 |
Net margin | -300,950% | - | - | - | - | - |
EPS 2 | - | - | -1.010 | -0.5000 | -1.000 | -1.060 |
Free Cash Flow 1 | - | - | - | -18 | -36 | -38 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 14/04/21 | 22/02/22 | 21/02/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | 1 | 45 | 7 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -18 | -36 | -38 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | -0.0100 | 1.220 | 0.1600 |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 14/04/21 | 22/02/22 | 21/02/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-40.06% | 3.53M | |
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- MODTX Stock
- Financials Modus Therapeutics Holding AB